These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15985503)

  • 1. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolites and safety: What are the concerns, and how should we address them?
    Smith DA; Obach RS
    Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA; Obach RS
    Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
    Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T; Lin JH; Baillie TA
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
    Baillie TA
    Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
    Timmerman P; Anders Kall M; Gordon B; Laakso S; Freisleben A; Hucker R
    Bioanalysis; 2010 Jul; 2(7):1185-94. PubMed ID: 21083233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL; Atrakchi A
    Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency.
    Yu H; Tweedie D
    Drug Metab Dispos; 2013 Mar; 41(3):536-40. PubMed ID: 23143892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 18. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of metabolite safety testing from an industry perspective.
    Anderson S; Knadler MP; Luffer-Atlas D
    Bioanalysis; 2010 Jul; 2(7):1249-61. PubMed ID: 21083238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.